Company Overview of Edgemont Pharmaceuticals, LLC
Edgemont Pharmaceuticals, LLC is a pharmaceutical company with a primary focus in the field of neuroscience. Its product pipeline includes EDG004 and EDG008, which are products to treat general anxiety disorder; EDG005, a product to treat major depressive disorder (MDD); EDG006, a product to treat treatment resistant depression; and EDG007, a product to treat menopausal vasomotor symptoms. The company also provides Fluoxetine, a product for the treatment of MDD, obsessive-compulsive disorder, bulimia nervosa, and panic disorder with or without agoraphobia in adults. Edgemont Pharmaceuticals, LLC was incorporated in 2006 and is based in Austin, Texas.
1250 Capital of Texas Highway, South
Austin, TX 78746
Founded in 2006
Key Executives for Edgemont Pharmaceuticals, LLC
Edgemont Pharmaceuticals, LLC Key Developments
Similar Private Companies By Industry
|1st Order Pharmaceuticals, Inc.||United States|
|21st Century Animal Health||United States|
|3 Buds' Organics LLC||United States|
|4P Therapeutics LLC||United States|
|60° Pharmaceuticals, LLC||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|The Advertising Council, Inc.||United States|
|NYC2012, Inc.||United States|
|Tax Management Inc||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Edgemont Pharmaceuticals, LLC, please visit www.edgemontpharma.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.